DxS receives Biotechnology Award for Cancer product from BioNow
DxS has won a 'biotechnology Project of the Year' award for its highly sensitive EGFR (Epidermal Growth Factor Receptor) Mutation Test Kit. Sponsored by the Manchester based law firm Pannone LLP, the award was presented by Bionow, the Northwest Regional Development Agency's (NWDA) biotechnology cluster support group, at the agency's annual awards ceremony in Cheshire, UK.
According to the company, recent advances in the field of cancer drugs have provided DxS with an opportunity to develop the world's first tumour mutation analysis kit to identify patients who will respond well to certain lung cancer therapies. This new oncogene assay can detect the 29 most common somatic mutations in the Epidermal Growth Factor Receptor Gene, identifying mutations that are not visible by sequencing techniques.
Most read news
Organizations
Other news from the department research and development

Get the analytics and lab tech industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.